TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer
June 04, 2018 at 05:00 pm IST
Share
TG Therapeutics, Inc. announced the appointment of Adam Waldman as Chief Commercial Officer. Mr. Waldman brings extensive experience commercializing products in oncology and hematology, most recently as the Head of US Hematology-Oncology Marketing at Celgene Corporation, and has an extensive track record of successfully launching multiple brands. Mr. Waldman joins TG Therapeutics with more than 20 years of experience in the biotechnology and life science industries. Most recently, Mr. Waldman served as the Head of US Hematology-Oncology Marketing at Celgene Corporation where he spent the past 13 years in various roles of increasing responsibility in sales, marketing and new product strategy.
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.